Literature DB >> 437552

Plasma glucagon in diabetes of haemochromatosis: too low or too high?

W A Muller, M Berger, H J Cüppers, P Berchtold, G Strohmeyer, A E Renold, J R Hofstetter, J J Gonvers.   

Abstract

Glucagon secretion before and during arginine infusions was tested in 11 patients with diabetes associated with haemochromatosis. The results were compared with those obtained in six normal subjects and five patients with haemochromatosis but normal glucose tolerance. The patients with haemochromatosis, regardless of glucose tolerance, exhibited higer level of plasma immunoreactivity for glucagon (antiserum 30-K) suggesting hyperglucagonaemia. However, additional analysis revealed that a considerable amount of this glucagon immunoreactivity was due to cross-reacting material of high molecular weight, the levels of which were significantly higher in patients with idiopathic haemochromatosis. When this was deducted from the total immunoreactivity measured, the resulting values for true glucagon concentrations were similar to those of normal subjects. The data suggest that (1) patients with idiopathic haemochromatosis, whether or not associated with diabetes, exhibit plasma glucagon levels comparable with those of normal subjects; (2) the plasma of the same patients contains significantly more high-molecular-weight substances reacting with glucagon antiserum 30-K than is present in plasma of normal subjects; and (3) 'hyperglucagonaemia' may be erroneously suggested when glucagon is measured with certain antisera reputed to be specific for glucagon.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 437552      PMCID: PMC1412294          DOI: 10.1136/gut.20.3.200

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

1.  Islet pathology in diabetes.

Authors:  W S HARTROFT
Journal:  Diabetes       Date:  1956 Mar-Apr       Impact factor: 9.461

2.  High molecular weight glucagon-like immunoreactivity in plasma.

Authors:  G C Weir; S D Knowlton; D B Martin
Journal:  J Clin Endocrinol Metab       Date:  1975-02       Impact factor: 5.958

3.  Hemochromatosis.

Authors:  A MARBLE; C C BAILEY
Journal:  Am J Med       Date:  1951-11       Impact factor: 4.965

4.  Glucagon secretion in diabetic patients with idiopathic haemochromatosis.

Authors:  P Passa; A S Luyckx; J L Carpentier; P J Lefebvre; J Canivet
Journal:  Diabetologia       Date:  1977-09       Impact factor: 10.122

5.  Characteristics of tissue IRGs in the dog.

Authors:  C B Srikant; K McCorkle; R H Unger
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

6.  Production and characterization of an antiserum against pancreatic glucagon.

Authors:  H Von Schenck
Journal:  Clin Chim Acta       Date:  1977-11-01       Impact factor: 3.786

7.  Circulating glucagon. Plasma profiles and metabolism in health and disease.

Authors:  J B Jaspan; A H Rubenstein
Journal:  Diabetes       Date:  1977-09       Impact factor: 9.461

8.  Abnormalities of glucagon metabolism in untreated diabetes mellitus.

Authors:  K D Buchanan; A M McCarroll
Journal:  Lancet       Date:  1972-12-30       Impact factor: 79.321

9.  Automation of a quantitative immunochemical microanalysis of human serum transferrin: a model system.

Authors:  I Eckman; J B Robbins; C J Van den Hamer; J Lentz; I H Scheinberg
Journal:  Clin Chem       Date:  1970-07       Impact factor: 8.327

10.  Radioimmunological determination of pancreatic and gut glucagon in plasma.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1971-02       Impact factor: 10.122

View more
  2 in total

1.  Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation?

Authors:  C Niederau; M Berger; W Stremmel; A Starke; G Strohmeyer; R Ebert; E Siegel; W Creutzfeldt
Journal:  Diabetologia       Date:  1984-06       Impact factor: 10.122

Review 2.  Diabetes in HFE Hemochromatosis.

Authors:  James C Barton; Ronald T Acton
Journal:  J Diabetes Res       Date:  2017-02-26       Impact factor: 4.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.